COVID-19 and Central Nervous System Manifestations: A Systemic review on Therapeutic Outcome



Khadga Raj1, G.D. Gupta2, Shamsher Singh3, *, Ankit Chaudhary1
1 Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India
2 Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India
3 Neuroscience Division, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India

Abstract

A novel caused the outbreak of coronavirus disease (COVID-19) has spread to Wuhan city of China and has become a global health issue and severe concern of the international community. Elderly patients with comorbidities, such as hypertension, diabetes mellitus, heart and lung disease, are more prone to COVID-19 Infection. COVID-19 and neurological disorders are two conditions with a well-documented association recently. Studies have shown that Infection with COVID-19 can alter the clinical spectrum of manifested neurological disorders and plays a vital role as long-term consequences in the development of diseases in the future. The SARS-CoV-2 virus reaches the brain either by an olfactory or by a hematogenous route pathway. Angiotensin-converting enzyme-2 (ACE-2) receptors, present in cerebral vessel endothelial cells of a cerebral vessel, are a potential viral entry point. Several cases of neurological disease have been identified recently, including Alzheimer's disease, Multiple sclerosis, and Parkinson's disease in COVID-19 patients, and a post-infectious immune-mediated inflammatory pathway has been held responsible for this. In this study, we try to explore the effect of COVID-19 on central nervous system damage and treatment of these manifestations. COVID-19 pandemic spreads to different parts of the world, the spectrum of neurological complications can expand further.

Keywords: COVID-19, ACE2 receptor, Neuropathology, Neurological disorders, Hydroxychloroquine.


Abstract Information


Identifiers and Pagination:

Year: 2021
Volume: 1
DOI: 10.2174/26669587-v1-e210709-2021-5

Article History:

Electronic publication date: 09/7/2021
Collection year: 2021

© 2021 Raj et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


* Address correspondence to this author at Neuroscience Division, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India; Tel: +91-9779980588; E-mail : shamshersinghbajwa@gmail.com